The global gene therapy market is undergoing a transformative evolution as healthcare systems increasingly shift toward precision medicine and curative therapies. According to recent industry analysis, the gene therapy market is projected to grow from USD 8.85 billion in 2024 to USD 36.55 billion by 2032, registering a robust CAGR of 19.4% during the forecast period. The rising burden of genetic disorders, rare diseases, and cancer, coupled with major advancements in genetic engineering technologies, is accelerating the adoption of gene therapy worldwide.
Gene therapy represents one of the most innovative areas in modern medicine. Unlike traditional treatments that primarily manage symptoms, gene therapy focuses on correcting defective genes or modifying cellular functions to address the root cause of diseases. This revolutionary therapeutic approach is gaining strong momentum across neurology, oncology, hematology, and several rare genetic disorders.
Rising Demand for Curative Therapies Driving Market Expansion
One of the major factors fueling market growth is the increasing demand for curative treatments for inherited and chronic diseases. Conditions such as spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), hemophilia, and certain cancers have shown promising outcomes with gene therapy interventions.
Healthcare providers and biopharmaceutical companies are heavily investing in gene-based treatments due to their long-term therapeutic potential. Unlike conventional drug therapies that require lifelong administration, many gene therapies are designed as one-time treatments, making them highly attractive for both patients and healthcare systems.
The clinical pipeline for gene therapy products is also expanding rapidly. According to industry estimates, approximately 19 new gene therapy products are expected to be launched between 2026 and 2032. These upcoming launches are anticipated to contribute nearly 25% of the projected USD 36.55 billion market value by 2032. Continuous innovation in viral vectors, genome editing technologies, and RNA-based therapeutics is further supporting this momentum.
Neurology Segment Dominates the Therapeutic Landscape
Based on therapeutic area, the neurology segment accounted for the largest share of the gene therapy market in 2023 and is expected to maintain its dominance throughout the forecast period.
The strong growth of this segment is primarily attributed to the increasing prevalence of neurological and neuromuscular disorders, along with the growing success of gene therapies targeting these conditions. Disorders such as spinal muscular atrophy, Duchenne muscular dystrophy, Parkinson’s disease, and limb-girdle muscular dystrophy are becoming key focus areas for research and commercialization.
Additionally, advancements in central nervous system (CNS) delivery technologies and growing investments in rare disease research are encouraging pharmaceutical companies to accelerate product development. The success of approved neurological gene therapies has also increased confidence among investors and regulatory agencies, creating favorable conditions for further innovation.
In Vivo Delivery Method Leads the Market
By delivery method, the in vivo segment dominated the gene therapy market in 2023 and is expected to witness the fastest growth over the coming years.
In vivo gene therapy involves delivering genetic material directly into the patient’s body using viral or non-viral vectors. This approach has gained widespread preference because it offers several advantages, including simplified treatment procedures, reduced manufacturing complexity, and broader therapeutic applicability.
Many commercially approved gene therapies currently utilize in vivo delivery systems, particularly those based on adeno-associated virus (AAV) vectors. Furthermore, the clinical pipeline is increasingly focused on in vivo approaches due to their ability to target tissues efficiently and deliver durable therapeutic outcomes.
Ex vivo gene therapy, where cells are modified outside the body before reinfusion, also remains an important segment, especially in oncology applications such as CAR-T cell therapies. However, the operational complexity and higher costs associated with ex vivo therapies continue to limit widespread adoption compared to in vivo methods.
Viral Vectors Continue to Play a Crucial Role
Vector technology remains a foundational component of the gene therapy market. Viral vectors, especially retroviral and adeno-associated virus (AAV) vectors, continue to dominate due to their high efficiency in delivering genetic material into target cells.
AAV vectors are particularly gaining traction because of their favorable safety profile and long-lasting gene expression capabilities. They are widely used in therapies targeting neurological, ophthalmic, and rare genetic diseases.
At the same time, non-viral vectors such as oligonucleotides are emerging as promising alternatives due to their lower immunogenicity and improved manufacturing scalability. Ongoing research aimed at improving delivery efficiency and reducing side effects is expected to expand opportunities within the non-viral vector segment.
North America Holds the Largest Market Share
Regionally, North America accounted for the largest share of the global gene therapy market in 2023. The region’s dominance is supported by a strong biotechnology ecosystem, high healthcare expenditure, and favorable regulatory frameworks.
The United States continues to lead the market due to the increasing number of gene therapy approvals from the FDA, significant investments in research and development, and the presence of major biotechnology and pharmaceutical companies. In addition, collaborations between academic institutions, biotech firms, and government organizations are accelerating innovation in gene-based therapeutics.
Europe also represents a significant market, supported by rising clinical trial activity and government initiatives promoting advanced therapies. Meanwhile, the Asia Pacific region is expected to witness the fastest growth during the forecast period due to expanding healthcare infrastructure, increasing biopharmaceutical investments, and growing awareness regarding precision medicine.
Countries such as China, Japan, and South Korea are emerging as important contributors to the global gene therapy landscape. The growing presence of regional biotech companies and supportive regulatory reforms are helping accelerate market development in these countries.
Challenges Limiting Market Growth
Despite its strong growth potential, the gene therapy market faces several challenges. One of the biggest concerns is the exceptionally high cost of gene therapy products. Many approved therapies are priced in the range of hundreds of thousands to millions of dollars per treatment, creating affordability and reimbursement challenges.
Limited manufacturing scalability also remains a critical issue. Producing gene therapies requires highly specialized facilities, advanced technologies, and stringent quality controls, which can limit production capacity and delay commercialization.
Additionally, concerns regarding long-term safety, immune responses, and regulatory complexities continue to present hurdles for market participants. However, ongoing technological advancements and increasing investments in manufacturing infrastructure are expected to gradually address these limitations.
Competitive Landscape
The gene therapy market is highly competitive, with several leading pharmaceutical and biotechnology companies actively investing in research, product development, and strategic collaborations. Key market players include Biogen Inc., Novartis AG, Alnylam Pharmaceuticals, Inc., Pfizer Inc., Johnson & Johnson Services, Inc., CRISPR Therapeutics, bluebird bio, Inc., and BioMarin Pharmaceutical Inc. among others.
These companies are focusing on expanding their product pipelines, strengthening manufacturing capabilities, and leveraging advanced technologies such as CRISPR gene editing, RNA therapeutics, and cell engineering to gain competitive advantages.
Conclusion
The global gene therapy market is entering a period of rapid expansion fueled by technological breakthroughs, increasing clinical success, and growing demand for personalized medicine. With continued innovation in vector technologies, delivery systems, and gene editing platforms, gene therapy is expected to reshape the future of healthcare over the next decade.
Although challenges related to cost and manufacturing remain significant, strong investment activity and an expanding clinical pipeline indicate a promising future for the industry. As more gene therapies receive regulatory approval and commercialization accelerates, the market is likely to witness unprecedented growth through 2032.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
